TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* One of the following diagnoses:~  1. Chronic myelogenous leukemia (CML) accelerated phase or second stable phase; individuals in the first chronic phase are eligible if they have resistance to imatinib~ 2. Myelodysplasia~ 3. Aplastic anemia that is not responding to immunosuppressive therapy~ 4. Myelofibrosis, either primary or secondary to polycythemia vera~ 5. Relapsed lymphoma or Hodgkin's disease~ 6. Stage III/IV chronic lymphocytic leukemia (CLL), relapsed after or refractory to at least one fludarabine containing regimen~ 7. Acute myelogenous leukemia (AML) or acute lymphoblastic leukemia (ALL) in complete remission (CR) 2 or greater, or CR 1 with high risk features~* No prior autologous stem cell transplant~* Eastern Cooperative Oncology Group (ECOG) performance status of less than 2~* Lack of 6/6 or 5/6 matched related donor OR lack of 10/10 matched unrelated donor OR no available donor in the appropriate time frame to perform a potentially curative stem cell transplant~* Diffusing capacity of the lung for carbon monoxide (DLCO) greater than 50% of predicted value~* Left ventricular ejection fraction (LVEF) greater than 50% of predicted value~* Calcium levels less than 10.5 mg/dl~* Phosphate levels greater than 1.6 mg/dl~Exclusion Criteria:~* Heart disease, as determined by symptomatic congestive heart failure, radionuclide ventriculogram (RVG), or echocardiogram-determined LVEF of less than 50%, active angina pectoris, or uncontrolled high blood pressure~* Pulmonary disease, as determined by severe chronic obstructive lung disease, symptomatic restrictive lung disease, or corrected DLCO of less than 50% of predicted value~* Kidney disease, as determined by serum creatinine levels greater than 2.0 mg/dl~* Liver disease, as determined by serum bilirubin levels greater than 2.0 mg/dl (except in the case of Gilbert's syndrome or hemolytic anemia in which the bilirubin can be elevated greater than 2.0mg/dl), SGOT or SGPT greater than 3 times the upper limit of normal~* Neurologic disease, as determined by symptomatic leukoencephalopathy, active central nervous system (CNS) cancer, or other neuropsychiatric abnormalities that may prevent transplantation (previous CNS cancer and presently in CR is acceptable)~* HIV antibodies~* Uncontrolled infection~* Pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Parathyroid Hormone (teriparatide) (Type: EXPERIMENTAL): Parathyroid hormone after double umbilical cord blood transplant.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: The Response Patterns to the Electrical Stimulation of Epidural Catheters With Varying Pulse Widths in Term Pregnant Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women 16 years of age and older requesting an epidural for labour analgesia~* Ability to communicate in English~* Informed consent~Exclusion criteria:~* Refusal to provide written informed consent~* Inability to communicate in English~* Abnormal vertebral anatomy, including but not limited to previous spine surgery and scoliosis~* Allergy or hypersensitivity to lidocaine, bupivacaine or fentanyl~* Coexisting neurological disorders~* Implanted electronic devices

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- 0.1ms pulse width (Type: ACTIVE_COMPARATOR): The nerve stimulator will be connected to the epidural catheter through an adapter, which will be primed with a standard volume of 3 ml of sterile normal saline to allow for effective electrical conduction. The cathode terminal of the stimulator will then be attached to the metal hub of the adapter and the anode terminal will be connected to the electrode placed over the deltoid muscle. All patients will have the trans-catheter electric stimulation test (TCEST) performed with both a 1 ms pulse width and 0.1 ms pulse width and the order of administration will be randomized.
- 1ms pulse width (Type: ACTIVE_COMPARATOR): The nerve stimulator will be connected to the epidural catheter through an adapter, which will be primed with a standard volume of 3 ml of sterile normal saline to allow for effective electrical conduction. The cathode terminal of the stimulator will then be attached to the metal hub of the adapter and the anode terminal will be connected to the electrode placed over the deltoid muscle. All patients will have the trans-catheter electric stimulation test (TCEST) performed with both a 1 ms pulse width and 0.1 ms pulse width and the order of administration will be randomized.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Transcorporal Versus Standard Artificial Urinary Sphincter Placement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients undergoing an AUS procedure would potentially be candidates for the study~Exclusion Criteria: There are several situations in which either a TC or ST procedure would be specifically indicated, and it would be unethical to randomize these patients to the other procedure.~* No men without erectile dysfunction~* No use of injectable agents into the corporal body~* No prior urethral surgery (Prior surgery defined as; urethroplasty, urethral sling, prior AUS placement or explantation, recto-urethral fistula closure)~* No current penile prosthesis~* No concomitant placement of penile prosthesis at the time of AUS placement~* Males under the age of 18, as well as females, are also excluded

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- STANDARD AUS Placement (Type: EXPERIMENTAL): Standard placement of an artificial urinary sphincter involves a small incision made in the patient's perineum or scrotum and a fluid-filled cuff is placed around the bulbar urethra (the portion of the urethra between the bladder neck and penis). Connected to the cuff with tubing, is a balloon filled with fluid that is placed behind the pubic bone or in the space between the peritoneum and abdominal muscles. A control pump is placed in the scrotum and allows the device to cycle, thus either exerting pressure to close off the urethra or releasing pressure to allow the urethra to open and the patient to void.
- TRANSCORPORAL AUS Placement (Type: EXPERIMENTAL): Transcorporal placement has been introduced as a way to reduce risk of erosion and involves tunneling the cuff through the erectile bodies. The same incision is made as for the standard approach, and then an incision is made in each corpus cavernosum (cylinders of tissue that allow for erection). This allows the cuff to be placed around both the urethra and through the lining of the corporal bodies, increasing the bulk of tissue behind the urethra to protect it from erosion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Y90 Radiation Segmentectomy vs SBRT for HCC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ability to provide written informed consent and HIPAA authorization~* Stated willingness to comply with all study procedures and availability for the duration of the study~* Male or female, aged ≥ 18 years at time of informed consent~* Solitary HCC (≤3 cm) diagnosed by imaging (LI-RADS 4-5) or histology~* Childs-Pugh score ≤ 7~* ECOG performance status 0-1~* Tumor location/characteristics eligible for either SBRT or Y90 therapy as deemed by local tumor board~* Adequate organ function defined as:~  1. serum bilirubin \< 4.0 mg/dL ,~ 2. albumin \> 2 g/dL~Exclusion Criteria:~* Any prior locoregional therapy to the target tumor~* Any prior radiation therapy to the liver~* Pregnancy or lactation: Women of childbearing potential must have a negative pregnancy test within 14 days of protocol registration. Women are considered to have childbearing potential (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) unless they meet one of the following criteria:~  i. Has undergone a hysterectomy or bilateral oophorectomy; or ii. Has been naturally amenorrheic for at least 24 consecutive months~* Known severe allergic reaction (anaphylaxis) to iodinated contrast~* Coagulopathy (platelets \< 50 K/mm3 and/or INR \> 2) not correctable by transfusion~* Macrovascular invasion or extrahepatic HCC

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Yttrium-90 Radiation Segmentectomy (Type: ACTIVE_COMPARATOR): None
- Stereotactic Body Radiation Therapy (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Methadone vs. Fentanyl Administration on Postoperative Pain Control in Pediatric Patients Undergoing Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age greater than or equal to 2 years and less than 8 years at the time of randomization.~2. Weight greater than 6 kg.~3. American Society of Anesthesiologists (ASA) physical status of ASA I, II, or III (Appendix I).~4. Informed consent to participate from the parent or legally authorized guardian.~5. Scheduled for congenital cardiac bypass surgery.~Exclusion Criteria~Subjects will not be eligible to participate in the study if any of the following exclusion criteria apply:~1. History or a family (parent or sibling) history of malignant hyperthermia.~2. Known significant hepatic disorders determined by medical history, medical record documentation, physical examination, or laboratory tests obtained during the routine preoperative cardiac surgery evaluation or cardiology visit (International Normalized Ratio (INR)\>1.5).~3. Emergency Cardiac Surgery.~4. History of chronic nausea and/or vomiting.~5. Currently receiving inotropic agents or using a pacemaker.~6. Prexisting long QTc interval of greater than 460ms determined by medical history, medical record documentation, or electrocardiogram obtained during the routine preoperative cardiac surgery evaluation.~7. History of documented pulmonary hypertension, respiratory dysfunction, or requirement of supplemental oxygen therapy.~8. History of opioid abuse, addiction, or tolerance.~9. Obesity defined as a body weight greater than 130% of the ideal weight.~10. Participation in another clinical trial or any study that may interfere with participation in this trial.~11. History of allergic reaction to methadone or fentanyl.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 7 Years
- Healthy Volunteers: t

Study Arms:
- Control - Fentanyl (Type: ACTIVE_COMPARATOR): Participants will receive 20 mcg/kg of fentanyl prior to surgical incision, over 20 minutes. The medication will be prepared as described and all research and staff personnel as well as the study participant will be blinded to treatment group assignment.
- Treatment - Methadone (Type: ACTIVE_COMPARATOR): Participants will receive 0.3 mg/kg of methadone prior to surgical incision, over 20 minutes. The medication will be prepared as described and all research and staff personnel as well as the study participant will be blinded to treatment group assignment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Cetuximab and Capecitabine in Treating Patients With Metastatic Colorectal Cancer That Failed Irinotecan Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of metastatic colorectal cancer~* Measurable disease~* Disease progression during prior fluoropyrimidine-containing therapy comprising irinotecan with or without oxaliplatin~  * Received standard first- and second-line irinotecan and oxaliplatin-based therapy~    * Patients who completed 1 prior treatment for metastatic disease but refused standard second-line therapy are eligible~ * Patients who's disease progressed within 6 months of previous therapy are eligible~* EGFR negative patients allowed~* No untreated or uncontrolled brain metastasis~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Absolute neutrophil count ≥ 1,500/μL~* Platelet count ≥ 100,000/μL~* ALT ≤ 5 times upper limit of normal (ULN)~* Alkaline phosphatase ≤ 5 times ULN~* Serum creatinine ≤ 1.5 mg/dL~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No other prior malignancy within the past 5 years except nonmelanoma skin cancer or carcinoma in situ of the cervix~* No serious intercurrent infections or medical problems~* No active or uncontrolled infections~* No significant history of uncontrolled cardiac disease, including any of the following:~  * Uncontrolled hypertension~ * Unstable angina~ * Myocardial infarction within the past 6 months~ * Uncontrolled congestive heart failure~ * Cardiomyopathy with decreased ejection fraction~* No prior severe infusion reaction to a monoclonal antibody~* No known dihydropyrimidine dehydrogenase deficiency or evidence of past hypersensitivity to fluoropyrimidine~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No more than 2 prior treatments for metastatic colorectal cancer~* More than 2 weeks since prior therapy~* Prior radiotherapy allowed if \< 30% of bone marrow involvement~* No other concurrent investigational agents~* No concurrent highly active antiretroviral therapy for HIV-positive patients~* No prior therapy that specifically and directly targets the EGFR pathway

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Cetuximab 400mg/m2 IV on day 1 over 2 hours then 250 mg/m2 over 1 hour weekly + Xeloda(Capecitabine) 1000mg/m2 BID on days 1-14 repeated every 21 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Conventional With Stereotactic Radiotherapy for Pain Reduction and Quality of Life in Spinal Metastases

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* solid tumor with radiological diagnosis of spinal metastases~* pain score minimum 2 on 11-point scale~* maximum of 2 consecutive or noncontiguous spinal vertebra involved by tumor at current level of interest~* No or mild neurological signs (radiculopathy, dermatomal sensory change and muscle strength of involved extremity)~* Karnofsky performance ≥60~* WHO ≤2~* life expectancy \> 6 weeks~* age ≥18~* non-pregnant, non-lactating female patients~Exclusion Criteria:~* history of previous radiotherapy to the spine at current level of interest~* spinal instability or neurological deficit~* pathological fracture or impending fracture needing fixation~* prior surgery to the spine at current level of interest~* clinical signs of spinal cord compression or severe neurological deficits~* patients with a pacemaker such that MRI cannot be performed or the treatment cannot be delivered safely~* patients unable to undergo MRI~* earlier nuclear medicine treatment~* pregnancy~* altered mental status that would prohibit the understanding and giving of informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: ACTIVE_COMPARATOR): Conventional radiotherapy, 1x8Gy
- Arm 2 (Type: EXPERIMENTAL): Stereotactic radiotherapy, 1x20Gy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Infergen and Ribavirin Treatment of Patients With HCV Who Achieved Partial Response to Peginterferon-alfa and Ribavirin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, at least 18 years of age and no older than 65 years with compensated chronic HCV infection based on a history of positive serum anti-HCV antibody and/or HCV RNA~* Diagnosed with HCV Genotype 1, 4, 5 or 6 as determined during the screening visit~* The starting doses in the initial treatment must have been 1.5 μg/kg/week PEG-Intron or 180 μg/week Pegasys, and 1000/1200 mg/day ribavirin based on body weight. Patients must have been at least 80% compliant during the initial peginterferon/ribavirin therapy, per patient account.~* Liver biopsy indicating F0-F4 must be performed within 3 years prior to screening. Documentation of the results of the biopsy must be available. If documentation is not available, a liver biopsy must be performed during the screening period. (A maximum of 10 patients in each of the three treatment groups will be patients with a fibrosis score of F4)~* Documented partial response after 12 weeks of treatment as a therapy-naive patient with one course of peginterferon alfa-2a (PEGASYS) and Ribavirin or peginterferon alfa-2b (Peg-INTRON) and Ribavirin~Exclusion Criteria:~* Detectable HCV RNA after 12 weeks if initial peginterferon alfa/ribavirin therapy and \<2 log decrease in HCV RNA at Week 12 from baseline.~* HCV Genotype 2 or 3~* Severe neuropsychiatric disorder.~* History or clinical manifestations of significant metabolic, hematological, pulmonary, ischemic heart disease, significant or unstable heart disease, gastrointestinal, neurological, renal, urological, endocrine, ophthalmologic disorders including severe retinopathy, or immune-mediated disease.~* Known HIV infection or positive HIV at screening.~* Pregnant or breast-feeding patients.~* Underlying autoimmune disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Infergen 15 ug QD plus RBV for 36 weeks
- 2 (Type: EXPERIMENTAL): Infergen 15 ug QD plus RBV for 48 weeks
- 3 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Serious Fungal Infection Due To Candida In Patients With A Dysfunctional Immune System

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Dysfunctional immune system (reduced neutrophils).~* Confirmed Candida infection, defined as growth of Candida from a normally sterile site accompanied by signs and symptoms of infection.~* Male of female ≥16 years of age.~* Expected hospitalization for at least ten (10) days.~Exclusion Criteria:~* Pregnancy or breast feeding or planning to become pregnant during the study.~* Recent treatment with one of the study drugs over the last 30 days.~* Allergy to either study drug or to this class of drugs.~* Significant liver dysfunction.~* Suspected Candida osteomyelitis, endocarditis, meningitis or any other infections of the central nervous system.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Anidulafungin Arm (Type: EXPERIMENTAL): Subjects were randomized 2:1 (anidulafungin:caspofunin).
- Caspofungin Arm (Type: EXPERIMENTAL): Subjects were randomized 2:1 (anidulafungin:caspofunin).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: 18F-Clofarabine PET/CT in Imaging Cancer Patients Before and After Interventions

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Must be able to tolerate PET/CT (i.e. not claustrophobic and able to remain supine)~* No restrictions based on gender or racial/ethnic background~Exclusion Criteria:~* Women of childbearing age will have to undergo a pregnancy test that will be provided free of charge

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Basic science (18F-clofarabine biodistribution) (Type: None): Patients receive 18F-clofarabine IV and undergo PET/CT scan at baseline and 2-4 weeks after completion of immunotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues